Summary: Robert Fine, MD, reported at a press conference held in advance of the 2014 Gastrointestinal Cancers Symposium (GICS), that the chemotherapy combination of capecitabine plus temozolomide either stalled disease progression or shrank tumors in 97% of patients whose disease had worsened after standard high-dose octreotide.
Read the full story at Medscape. You can sign up for a free account to access the full article.